Cullinan Therapeutics, Inc. Income Statement

Income Statement Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Revenue & cost
Revenue 18.94M
Gross Profit 18.94M
Operating items
Research & Development 43.21M57.75M91.95M148.16M142.90M
Selling, General & Administrative 17.12M29.15M40.19M42.49M54.02M
Operating Expenses 60.34M86.90M132.14M190.65M196.92M
Operating Income -60.34M-67.95M144.65M-191.09M-196.92M
EBIT -60.34M-67.95M144.65M-191.09M-196.92M
Non-operating items
Interest & Investment Income 0.89M0.48M6.61M21.63M29.66M
Other Non Operating Income -0.01M-0.01M0.06M0.24M-0.20M
Non Operating Income -0.01M-0.01M0.06M0.24M-0.20M
Net income details
EBT -59.45M-67.48M151.32M-169.22M-167.46M
Tax Provisions 42.12M-14.12M0.12M
Profit After Tax -59.46M-67.48M111.21M-155.10M-167.57M
Income from Non-Controlling Interests 7.70M-1.92M-2.02M-1.94M-0.19M
Income from Continuing Operations -59.45M-67.48M109.19M-155.10M-167.57M
Consolidated Net Income -59.45M-67.48M109.19M-155.10M-167.57M
Income towards Parent Company -59.45M-67.48M109.19M-155.10M-167.57M
Net Income towards Common Stockholders -59.45M-67.48M109.19M-155.10M-167.57M
Additional items
EPS (Basic) -0.00M-0.00M0.00M-0.00M-0.00M
EPS (Weighted Average and Diluted) -0.00M0.00M-0.00M-0.00M
Shares Outstanding (Weighted Average) 37.83M43.68M45.77M42.78M58.23M
Shares Outstanding (Diluted Average) 43.08M46.64M
EBITDA -59.46M-68.32M144.65M-191.09M-196.92M
Shares Outstanding 29.83M44.29M45.80M
Tax Rate 0.00M0.00M